(Q48935307)

English

Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.

scientific article published on 7 October 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/26447645

Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/26447645

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Vincenzo Triggiani

8

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/26447645

author name string

V A Giagulli

1

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/26447645

M D Carbone

2

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/26447645

M I Ramunni

3

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/26447645

B Licchelli

4

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/26447645

G De Pergola

5

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/26447645

C Sabbà

6

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/26447645

E Guastamacchia

7

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/26447645

publication date

7 October 2015

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/26447645

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/26447645

3

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/26447645

6

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/26447645

1094-1103

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/26447645

Testosterone concentrations in women and men with NIDDM.

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Pharmacological management of obesity: an endocrine Society clinical practice guideline.

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism.

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Type 2 diabetes mellitus and testosterone: a meta-analysis study.

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Testosterone supplementation and sexual function: a meta-analysis study

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Possible role of hyperinsulinemia and insulin resistance in lower vitamin D levels in overweight and obese patients

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Effect of testosterone treatment on constitutional and sexual symptoms in men with type 2 diabetes in a randomized, placebo-controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Modifying risk factors to prevent and treat erectile dysfunction

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Low testosterone levels are common and associated with insulin resistance in men with diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Clinical review: Klinefelter syndrome--a clinical update.

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study).

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Testosterone with dutasteride, but not anastrazole, improves insulin sensitivity in young obese men: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

The decline of androgen levels in elderly men and its clinical and therapeutic implications

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Management of hyperglycemic crises in patients with diabetes

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Sex steroids affect triglyceride handling, glucose-dependent insulinotropic polypeptide, and insulin sensitivity: a 1-week randomized clinical trial in healthy young men.

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Definitions/epidemiology/risk factors for sexual dysfunction

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Relaxation of androgens on rat thoracic aorta: testosterone concentration dependent agonist/antagonist L-type Ca2+ channel activity, and 5beta-dihydrotestosterone restricted to L-type Ca2+ channel blockade.

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

The relationships between sex hormones and sexual function in middle-aged and older European men.

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

The International Index of Erectile Function (IIEF): a state-of-the-science review

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients.

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Intensive insulin therapy increases sex hormone-binding globulin in newly diagnosed type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Effect of intensive glycemic therapy on erectile function in men with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Improved erectile function after Rho-kinase inhibition in a rat castrate model of erectile dysfunction

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.

1 reference

https://api.crossref.org/works/10.1111%2FANDR.12099

21 January 2018

Identifiers

10.1111/ANDR.12099

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/26447645

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/26447645

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48935307&oldid=1579792000"